Editas Medicine Inc
(LTS:0IFK)
$
2.8211
+0.016 (+0.57%)
Market Cap: 443.85 Mil
Enterprise Value: 247.71 Mil
PE Ratio: 0
PB Ratio: 4.21
GF Score: 56/100 
Editas Medicine Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2026 / 12:00PM GMT
Release Date Price:
$2.53
(-3.59%)
Jasmine Fels
Barclays Services Corp - Analyst
Okay. Hi, everyone, good morning. Thank you for joining us. I'm Jasmine Fels. I'm one of the biotech analysts here at Barclays. And we're very happy to have Editas Medicine here with us today. So we have Gilmore O'Neill, who is the President and CEO; and Amy Parison, who's the CFO. So thank you both for joining us
Questions & Answers
Amy Parison
Editas Medicine Inc - Chief Financial Officer, Senior Vice President, Treasurer
Thank you.
Gilmore O;Neill
Editas Medicine Inc - President, Chief Executive Officer, Director
' -
It's great to be with you
Jasmine Fels;Gilmore O;Neill
Barclays Services Corp - Analyst;Editas Medicine Inc - President, Chief Executive
Great. Okay. All right. Let's start with the basics. So can you give an overview of your platform and your approach to gene editing and how that's differentiated from others in the broader space.
'
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers